Indeed, aberrant NF-κB activation is a hallmark of most human neoplasias, where it drives oncogenesis, disease recurrence and therapy resistance, largely by inducing a transcriptional programme that suppresses apoptosis of cancer cells and orchestrates the inflammatory reaction in the tumour microenvironment (TME) [7]. This evidence concerns the gene NFKB1 and neoplasm.